Form 4: Precision BioSciences: Executive Awarded Stock Units

Precision BioSciences reports the grant of 57,389 restricted stock units to Chief Research Officer J. Jefferson Smith.

Summary

• J. Jefferson Smith, Chief Research Officer at Precision BioSciences, Inc., was granted 57,389 restricted stock units (RSUs) on June 1, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit.
• The award vests in three substantially equal annual installments, commencing on February 19, 2027.
• Vesting is contingent upon Mr. Smith's continued service to the Issuer through each applicable vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard executive compensation award rather than a significant financial or strategic development.

Positives

• Grant of restricted stock units to a key executive, indicating a commitment to retaining talent.
• The award is structured to vest over time, aligning the executive's incentives with long-term company performance.

Risks

• Vesting is contingent on continued service, meaning the executive could forfeit unvested units if they leave the company before the vesting dates.
• The value of the RSUs is tied to the performance of Precision BioSciences' common stock, which is subject to market volatility.

Future Outlook

The future outlook for the restricted stock units is dependent on the continued service of J. Jefferson Smith and the performance of Precision BioSciences' common stock.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units is a common practice in the biotechnology sector for executive compensation and talent retention, particularly for key research personnel driving innovation.

Stakeholder Impact

• Shareholders: The award is a form of compensation, impacting potential dilution if RSUs are settled in stock, but also aims to retain key talent for long-term value creation.
• Employees: May signal the company's commitment to rewarding its research leadership, potentially impacting morale.
• Management: Reinforces the incentive structure for J. Jefferson Smith to remain with the company and contribute to its success.

Next Steps

• J. Jefferson Smith is expected to continue his service to the Issuer through the vesting dates.
• The restricted stock units will vest in three substantially equal annual installments starting February 19, 2027.

Key Dates

Keywords

restricted stock units, executive compensation, Precision BioSciences, DTIL, stock award, insider trading, Form 4